These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 26576555)

  • 1. Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany.
    Petersen J; Heyne R; Mauss S; Schlaak J; Schiffelholz W; Eisenbach C; Hartmann H; Wiese M; Boeker K; Loehr HF; John C; Leuschner M; Trautwein C; Felten G; Trein A; Krause W; Ruppert S; Warger T; Hueppe D
    Dig Dis Sci; 2016 Oct; 61(10):3061-3071. PubMed ID: 26576555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France.
    Marcellin P; Zoulim F; Hézode C; Causse X; Roche B; Truchi R; Pauwels A; Ouzan D; Dumortier J; Pageaux GP; Bourlière M; Riachi G; Zarski JP; Cadranel JF; Tilliet V; Stern C; Pétour P; Libert O; Consoli SM; Larrey D
    Dig Dis Sci; 2016 Oct; 61(10):3072-3083. PubMed ID: 26821154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.
    Idilman R; Gunsar F; Koruk M; Keskin O; Meral CE; Gulsen M; Elhan AH; Akarca US; Yurdaydin C
    J Viral Hepat; 2015 May; 22(5):504-10. PubMed ID: 25431108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
    Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E
    Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of tenofovir in nucleos(t)ide-naïve patients with genotype C chronic hepatitis B in real-life practice.
    Kim JH; Jung SW; Byun SS; Shin JW; Park BR; Kim MH; Kim CJ; Park NH
    Int J Clin Pharm; 2015 Dec; 37(6):1228-34. PubMed ID: 26364195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical effect of entecavir versus tenofovir in treatment of HBeAg-positive chronic hepatitis B patients with a high viral load: a comparative analysis].
    Shi H; Li XY; Zhu JY; Lin CS; Zhang Y
    Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):721-725. PubMed ID: 29108198
    [No Abstract]   [Full Text] [Related]  

  • 7. Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients.
    Chung GE; Cho EJ; Lee JH; Yoo JJ; Lee M; Cho Y; Lee DH; Kim HY; Yu SJ; Kim YJ; Yoon JH; Zoulim F
    Clin Mol Hepatol; 2017 Mar; 23(1):66-73. PubMed ID: 28190329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study.
    Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Kim K; Kitrinos KM; Subramanian GM; McHutchison JG; Yee LJ; Elkhashab M; Berg T; Sporea I; Yurdaydin C; Husa P; Jablkowski MS; Gane E
    J Hepatol; 2017 Jan; 66(1):11-18. PubMed ID: 27545497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection.
    Marcellin P; Wong DK; Sievert W; Buggisch P; Petersen J; Flisiak R; Manns M; Kaita K; Krastev Z; Lee SS; Cathcart AL; Crans G; Op den Brouw M; Jump B; Gaggar A; Flaherty J; Buti M
    Liver Int; 2019 Oct; 39(10):1868-1875. PubMed ID: 31136052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection.
    Buti M; Tsai N; Petersen J; Flisiak R; Gurel S; Krastev Z; Aguilar Schall R; Flaherty JF; Martins EB; Charuworn P; Kitrinos KM; Subramanian GM; Gane E; Marcellin P
    Dig Dis Sci; 2015 May; 60(5):1457-64. PubMed ID: 25532501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients.
    Kim HJ; Cho JY; Kim YJ; Gwak GY; Paik YH; Choi MS; Koh KC; Paik SW; Yoo BC; Lee JH
    Korean J Intern Med; 2015 Jan; 30(1):32-41. PubMed ID: 25589833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
    Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ
    Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients.
    Jung SK; Kim KA; Ha SY; Lee HK; Kim YD; Lee BH; Paik WH; Kim JW; Bae WK; Kim NH; Lee JS; Jwa YJ
    Clin Mol Hepatol; 2015 Mar; 21(1):41-8. PubMed ID: 25834801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
    Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
    Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of switching from lamivudine+adefovir to tenofovir disoproxil fumarate in virologically suppressed patients.
    Fasano M; Maggi P; Leone A; Volpe A; Fiore JR; Angarano G; Santantonio TA
    Dig Liver Dis; 2017 May; 49(5):530-534. PubMed ID: 28179096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort.
    Ahn SS; Chon YE; Kim BK; Kim SU; Kim DY; Ahn SH; Han KH; Park JY
    Clin Mol Hepatol; 2014 Sep; 20(3):261-6. PubMed ID: 25320729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B.
    Pan CQ; Chan S; Trinh H; Yao A; Bae H; Lou L
    World J Gastroenterol; 2015 May; 21(18):5524-31. PubMed ID: 25987775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
    Heathcote EJ; Marcellin P; Buti M; Gane E; De Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Gurel S; Snow-Lampart A; Borroto-Esoda K; Mondou E; Anderson J; Sorbel J; Rousseau F
    Gastroenterology; 2011 Jan; 140(1):132-43. PubMed ID: 20955704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.
    Liu Y; Corsa AC; Buti M; Cathcart AL; Flaherty JF; Miller MD; Kitrinos KM; Marcellin P; Gane EJ
    J Viral Hepat; 2017 Jan; 24(1):68-74. PubMed ID: 27658343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years.
    Buti M; Fung S; Gane E; Afdhal NH; Flisiak R; Gurel S; Flaherty JF; Martins EB; Yee LJ; Dinh P; Bornstein JD; Mani Subramanian G; Janssen HL; George J; Marcellin P
    Hepatol Int; 2015 Apr; 9(2):243-50. PubMed ID: 25788199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.